FCF Life Sciences
Venture Capital Monitor
-
Europe

The FCF Life Sciences Venture Capital Monitor – Europe is a monthly published overview of biotechnology, pharmaceutical, medical technology and healthcare technology companies, displaying Venture capital financing trends in the European Life Sciences industry.

FCF Life Sciences Venture Capital Monitor - Europe
ETC.....
Previous
Next

As of the end of September 2021 we identify the following current VC trends in Europe:

  • In 2021, overall Life Sciences funding has reached EUR 9,955m so far
  • Top 5 Deals exceed EUR 190m each, largest transaction amounted to EUR 497m in CMR Surgical Ltd. (United Kingdom)
  • BlackRock (USA) still dominates the Top 5 Investors (by deal volume), followed by Fidelity Management & Research (USA) and Novo Holdings (Denmark)
  • The Biotechnology sector received 43% of the total investment volume (-7% points compared to the previous month)
  • Oncology dominates as the top indication
FCF Life Sciences Venture Capital Monitor - Europe
ETC.....
Previous
Next

Capital Markets Research

We constantly engage in capital markets research to identify financing trends early in the Life Sciences sector. Our research focuses on the most relevant equity markets: Venture Capital, Public Equity, Initial Public Offerings (IPO). The findings are currently published in the following publications:

NEWS

Psychedelics attract more VC investments

Investment into US and European psychedelics companies have been continuously increasing over the past years as mental health gains in importance. Whereas only 12 venture capital transactions were conducted in 2016, the number of transactions

Read more »